International Association for the Study of Lung Cancer

#WCLC Conference Chair Dr. Noemí Reguart discusses how this year's program builds on multidisciplinary collaboration, cutting-edge #research, and global perspectives in #thoraciconcology.

🎉 Congrats to Dr. Thamires Oliveira Silva, MD, at D'Or Institute for Research and Education! One of our 2025 Young Investigator Awardees! Their project, 𝘎𝘦𝘯𝘰𝘮𝘦-𝘸𝘪𝘥𝘦 𝘋𝘕𝘈 𝘔𝘦𝘵𝘩𝘺𝘭𝘢𝘵𝘪𝘰𝘯 𝘈𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘪𝘯 𝘗𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘌𝘍𝘎𝘙-𝘮𝘶𝘵𝘢𝘯𝘵 𝘓𝘶𝘯𝘨 𝘈𝘥𝘦𝘯𝘰𝘤𝘢𝘳𝘤𝘪𝘯𝘰𝘮𝘢, investigates whether specific DNA methylation patterns in EGFR-mutated NSCLC define prognostic subgroups and influence response to third-generation TKIs such as osimertinib. By analyzing tumor methylomes, we aim to identify patients with intrinsic resistance despite sensitizing EGFR mutations. Findings may inform personalized treatment strategies, refine escalation/de-escalation decisions, and advance precision medicine in thoracic oncology. We’re excited to see where this research leads, way to go, Dr. Silva! 👏

On a new episode of Lung Cancer Considered, Dr. Stephen Liu and Dr. Narjust Florez M.D. FASCO are joined by Summer Farmen, Nancee Pronsati, and Kirk Smith. They share highlights from the ALK+ Summit, reflect on the importance of patient advocacy, and explore how events like this strengthen the lung cancer community. 🎧 Listen here: https://bit.ly/ALKSummit #LungCancer #ALKPlus #PatientAdvocacy #Podcast

🎉 Congrats to Dr. David O’Reilly, Medical Oncology Fellow at the Beaumont Hospital. One of our 2025 Adi F. Gazdar Fellowship Awardees! Their project, 𝘔𝘶𝘭𝘵𝘪-𝘰𝘮𝘪𝘤 𝘦𝘹𝘩𝘢𝘭𝘦𝘥 𝘣𝘳𝘦𝘢𝘵𝘩 𝘢𝘯𝘥 𝘱𝘭𝘢𝘴𝘮𝘢 𝘣𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳𝘴 𝘵𝘰 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝘧𝘳𝘰𝘮 𝘤𝘩𝘦𝘮𝘰-𝘪𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘥 𝘕𝘚𝘊𝘓𝘊, aims to develop early, non-invasive methods to assess treatment response in patients with advanced (stage III or IV) non-small cell lung cancer (NSCLC) who do not have oncogene-addicted tumors (e.g., ALK or EGFR alterations). Current practice involves CT scans approximately three months after initiating immunotherapy. We’re excited to see where this research leads, way to go, Dr. O’Reilly! 👏

🎉 Congrats to Dr. Komal Gupta, Research Scientist in the Cancer Therapeutics Research Laboratory at the National Cancer Centre Singapore (NCCS)! One of our 2025 Adi F. Gazdar Fellowship Awardees! Their project, 𝘜𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘖𝘳𝘪𝘨𝘪𝘯𝘴 𝘢𝘯𝘥 𝘐𝘮𝘱𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴 𝘰𝘧 𝘊𝘩𝘳𝘰𝘮𝘰𝘴𝘰𝘮𝘢𝘭 𝘐𝘯𝘴𝘵𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘪𝘯 𝘌𝘎𝘍𝘙-𝘔𝘶𝘵𝘢𝘵𝘦𝘥 𝘓𝘶𝘯𝘨 𝘊𝘢𝘯𝘤𝘦𝘳 𝘪𝘯 𝘕𝘦𝘷𝘦𝘳 𝘚𝘮𝘰𝘬𝘦𝘳𝘴 (𝘓𝘊𝘐𝘕𝘚), investigates why non-small cell lung cancer (NSCLC) develops in never smokers, particularly those with EGFR mutations, which are more common in East Asian women. Their research focuses on chromosomal instability (CIN), a condition in which genetic material becomes disorganized, as a key driver of cancer progression and treatment resistance. By understanding how EGFR mutations promote CIN, the project aims to develop a tool for early detection, helping to predict relapse and guide personalized treatment strategies. We’re excited to see where this research leads, way to go, Dr. Gupta! 👏

How are ALK-positive NSCLC cases approached in Greece? In this Greek-language episode of Lung Cancer Considered, Dr. Giannis Mountzios moderates a Virtual Tumor Board with Dr. Petros Christopoulos and Dr. Dionysis Papadatos-Pastos. Together, they review treatment strategies and clinical considerations for patients with ALK-positive NSCLC. 🎧 Listen now: https://bit.ly/GreekALKVTB #LungCancerConsidered #ALK #NSCLC #LungCancer #Oncology #Greece

🎉 Congrats to Dr. Zhen Zeng, Research Associate at Johns Hopkins University School of Medicine! One of our 2025 LCFA/IASLC Translational Research Grants in Thoracic Oncology Awardees! Their project, 𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘰𝘧 𝘢 𝘨𝘦𝘯𝘦 𝘴𝘪𝘨𝘯𝘢𝘵𝘶𝘳𝘦 𝘭𝘪𝘯𝘬𝘪𝘯𝘨 𝘵𝘶𝘮𝘰𝘳-𝘳𝘦𝘢𝘤𝘵𝘪𝘷𝘦 𝘛𝘐𝘓 𝘴𝘱𝘢𝘵𝘪𝘢𝘭 𝘪𝘯𝘵𝘦𝘳𝘢𝘤𝘵𝘪𝘰𝘯𝘴 𝘳𝘦𝘭𝘢𝘵𝘦𝘥 𝘵𝘰 𝘪𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴, refines MANAscore, a bioinformatics tool to identify tumor-reactive TIL in lung cancer, by integrating spatial technologies to map their interactions in the tumor microenvironment. Findings may improve prediction of immunotherapy response and guide personalized treatment. We’re excited to see where this research leads, way to go, Dr. Zeng! 👏

🎉 Congrats to Dr. Pedro Rocha, Medical Oncologist at Vall d’Hebron University Hospital! One of our 2025 Young Investigator Awardees! Their project, 𝘚𝘦𝘹-𝘉𝘢𝘴𝘦𝘥 𝘉𝘪𝘰𝘮𝘢𝘳𝘬𝘦𝘳𝘴 𝘢𝘯𝘥 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘗𝘳𝘰𝘧𝘪𝘭𝘦𝘴 𝘢𝘴 𝘗𝘳𝘦𝘥𝘪𝘤𝘵𝘰𝘳𝘴 𝘰𝘧 𝘉𝘪𝘛𝘌𝘴 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘙𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘪𝘯 𝘚𝘮𝘢𝘭𝘭 𝘊𝘦𝘭𝘭 𝘓𝘶𝘯𝘨 𝘊𝘢𝘯𝘤𝘦𝘳, explores sex-specific biomarkers of response to BiTE therapy in ES-SCLC. Using blood and tissue samples from our biobank, they will apply single-cell RNA and T-cell receptor sequencing to track immune changes during treatment, aiming to explain observed sex-based differences in efficacy and guide personalized therapy. We’re excited to see where this research leads, way to go, Dr. Rocha! 👏

🎉 Congrats to Jin Ng, PhD, Senior Research Officer at the WEHI (Walter and Eliza Hall Institute of Medical Research). One of our 2025 Young Investigator Awardees! Their project, 𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘪𝘯𝘨 𝘗𝘳𝘦𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘔𝘰𝘥𝘦𝘭𝘴 𝘰𝘧 𝘛𝘢𝘳𝘭𝘢𝘵𝘢𝘮𝘢𝘣 𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘤𝘦 𝘪𝘯 𝘚𝘮𝘢𝘭𝘭 𝘊𝘦𝘭𝘭 𝘓𝘶𝘯𝘨 𝘊𝘢𝘯𝘤𝘦𝘳 𝘢𝘯𝘥 𝘌𝘹𝘱𝘭𝘰𝘳𝘪𝘯𝘨 𝘕𝘦𝘸 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵𝘴, aims to advance better treatments for SCLC patients worldwide, especially those who don’t respond to current therapies by understanding resistance and exploring new options. We’re excited to see where this research leads, way to go, Dr. Ng! 👏

🎉 Congrats to Dr. Daniel Lu, Postdoctoral researcher at Memorial Sloan Kettering Cancer Center. One of our 2025 Adi F. Gazdar Fellowship Awardees! Their project, 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘳𝘰𝘭𝘦 𝘰𝘧 𝘚𝘌𝘛𝘋2 𝘢𝘯𝘥 𝘪𝘵𝘴 𝘭𝘰𝘴𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘪𝘯𝘪𝘵𝘪𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘮𝘢𝘪𝘯𝘵𝘦𝘯𝘢𝘯𝘤𝘦 𝘰𝘧 𝘉𝘙𝘈𝘍𝘝600𝘌 𝘢𝘯𝘥 𝘙𝘌𝘛-𝘧𝘶𝘴𝘪𝘰𝘯 𝘥𝘳𝘪𝘷𝘦𝘯 𝘭𝘶𝘯𝘨 𝘤𝘢𝘯𝘤𝘦𝘳, explores how loss of the tumour suppressor SETD2 promotes lung cancer, especially in cases with BRAF or RET fusions. They aim to understand how SETD2 loss alters gene expression and cooperates with these mutations to drive tumour growth. Using lung cell models, they will identify potential vulnerabilities that could lead to new treatments. We’re excited to see where this research leads, way to go, Dr. Lu! 👏